                               SEQUENCE LISTING

<110> ALTOR BIOSCIENCE CORPORATION
 
<120> ALT-803 IN COMBINATION WITH ANTI-CD38 ANTIBODY FOR CANCER 
      THERAPIES

<130> 048277-531001WO

<140> PCT/US2018/025366
<141> 2018-03-30

<150> 15/937,493
<151> 2018-03-27

<150> 62/480,339
<151> 2017-03-31

<160> 6     

<170> PatentIn version 3.5

<210> 1
<211> 405
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 1
atggagacag acacactcct gttatgggta ctgctgctct gggttccagg ttccaccggt       60

aactgggtga atgtaataag tgatttgaaa aaaattgaag atcttattca atctatgcat      120

attgatgcta ctttatatac ggaaagtgat gttcacccca gttgcaaagt aacagcaatg      180

aagtgctttc tcttggagtt acaagttatt tcacttgagt ccggagatgc aagtattcat      240

gatacagtag aaaatctgat catcctagca aacgacagtt tgtcttctaa tgggaatgta      300

acagaatctg gatgcaaaga atgtgaggaa ctggaggaaa aaaatattaa agaatttttg      360

cagagttttg tacatattgt ccaaatgttc atcaacactt cttaa                      405


<210> 2
<211> 134
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 2
Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Gly Ser Thr Gly Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile 
            20                  25                  30          


Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu 
        35                  40                  45              


Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu 
    50                  55                  60                  


Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His 
65                  70                  75                  80  


Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asp Ser Leu Ser Ser 
                85                  90                  95      


Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu 
            100                 105                 110         


Glu Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln 
        115                 120                 125             


Met Phe Ile Asn Thr Ser 
    130                 


<210> 3
<211> 114
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 3
Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile 
1               5                   10                  15      


Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His 
            20                  25                  30          


Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln 
        35                  40                  45              


Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu 
    50                  55                  60                  


Asn Leu Ile Ile Leu Ala Asn Asp Ser Leu Ser Ser Asn Gly Asn Val 
65                  70                  75                  80  


Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile 
                85                  90                  95      


Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn 
            100                 105                 110         


Thr Ser 
        


<210> 4
<211> 951
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polynucleotide

<400> 4
atggacagac ttacttcttc attcctgctc ctgattgtcc ctgcgtacgt cttgtccatc       60

acgtgccctc cccccatgtc cgtggaacac gcagacatct gggtcaagag ctacagcttg      120

tactccaggg agcggtacat ttgtaactct ggtttcaagc gtaaagccgg cacgtccagc      180

ctgacggagt gcgtgttgaa caaggccacg aatgtcgccc actggacaac ccccagtctc      240

aaatgtatta gagagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca      300

cctgaactcc tggggggacc gtcagtcttc ctcttccccc caaaacccaa ggacaccctc      360

atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct      420

gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg      480

cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag      540

gactggctga atggcaagga gtacaagtgc aaggtctcca acaaagccct cccagccccc      600

atcgagaaaa ccatctccaa agccaaaggg cagccccgag aaccacaggt gtacaccctg      660

cccccatccc gggatgagct gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc      720

ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac      780

aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctacag caagctcacc      840

gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct      900

ctgcacaacc actacacgca gaagagcctc tccctgtctc cgggtaaata a               951


<210> 5
<211> 316
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 5
Met Asp Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr 
1               5                   10                  15      


Val Leu Ser Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp 
            20                  25                  30          


Ile Trp Val Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys 
        35                  40                  45              


Asn Ser Gly Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys 
    50                  55                  60                  


Val Leu Asn Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu 
65                  70                  75                  80  


Lys Cys Ile Arg Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 
                85                  90                  95      


Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 
            100                 105                 110         


Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 
        115                 120                 125             


Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 
    130                 135                 140                 


Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 
145                 150                 155                 160 


Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 
                165                 170                 175     


Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 
            180                 185                 190         


Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 
        195                 200                 205             


Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 
    210                 215                 220                 


Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 
225                 230                 235                 240 


Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 
                245                 250                 255     


Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 
            260                 265                 270         


Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 
        275                 280                 285             


Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 
    290                 295                 300                 


Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
305                 310                 315     


<210> 6
<211> 297
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 6
Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val 
1               5                   10                  15      


Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly 
            20                  25                  30          


Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn 
        35                  40                  45              


Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile 
    50                  55                  60                  


Arg Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 
65                  70                  75                  80  


Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 
                85                  90                  95      


Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 
            100                 105                 110         


Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 
        115                 120                 125             


Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 
    130                 135                 140                 


Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 
145                 150                 155                 160 


Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 
                165                 170                 175     


Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 
            180                 185                 190         


Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 
        195                 200                 205             


Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 
    210                 215                 220                 


Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 
225                 230                 235                 240 


Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 
                245                 250                 255     


Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 
            260                 265                 270         


Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 
        275                 280                 285             


Lys Ser Leu Ser Leu Ser Pro Gly Lys 
    290                 295         


